Quiz

Article

Clinical Quiz: AGA Guideline for Fecal Microbiota-Based Therapies in Gastrointestinal Disease

Test your knowledge of the AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases with this clinical quiz!

On February 21, 2024, the American Gastroenterological Association (AGA) released the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal diseases. A guideline panel developed 7 recommendations intended to provide the basis for rational, informed decision-making for patients and healthcare professionals using fecal microbiota-based therapies for adults with recurrent Clostridioides difficile infection (CDI), severe to fulminant CDI, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).

In this clinical quiz, test your knowledge of the clinical recommendations for the use of fecal microbiota-based therapies in the 2024 American Gastroenterological Association Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.

What does the AGA suggest regarding fecal microbiota-based therapies in severely immunocompromised adults with recurrent CDI?



Reference:

  1. Peery AF, Kelly CR, Kao D, et al. American Gastroenterological Association Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. https://www.gastrojournal.org/article/S0016-5085(24)00041-6/fulltext
Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.